775 On Other Exchanges
775 is not on other exchanges.

ck life sciences intl hldgs (775) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CK LIFE SCIENCES INTL HLDGS (775)

Related News

No related news articles were found.

ck life sciences intl hldgs (775) Related Businessweek News

No Related Businessweek News Found

ck life sciences intl hldgs (775) Details

CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, engages in the research and development, manufacture, commercialization, marketing, and sale of health and agriculture-related products in the Asia Pacific and North America. It manufactures and markets plant protection products and soluble fertilizers; manufactures, blends, distributes, and sells fertilizers, pesticides, and related agricultural products; manufactures and distributes horticultural products for the home gardening market; and contract manufactures complementary healthcare medicines and produces non-sterile prescription and over-the-counter medicines, as well as cosmetics. The company is also involved in licensing registration activities and the importation of finished agricultural goods; holding land and building; financing and trustee activities; investment in financial instruments, as well as vineyards and wineries; trading biotechnology products and nutritional supplements; and the manufacture, wholesale, retail, and distribution of nutraceutical products. In addition, it distributes turf management machinery, hardware, equipment, and accessories, as well as chemicals and professional pest products; produces, refines, and distributes salt products; and provides services in the research and development of bio-technology and life sciences technology products. The company’s products include emulsifiable concentrates, suspension concentrates, aqueous solutions, coated granules, powders, and amination based reactions for crop protection; and pharmaceutical products, such as POL-103A and Tetrodotoxin that are in advanced stages of clinical development for the treatment of cancer. Further, it engages in the discovery, development, manufacture, and commercialization of drug products to treat pain; development of Melanoma vaccine, which is in Phase III clinical trial; and supply of raw materials for various segments. The company is headquartered in Tai Po, Hong Kong.

1,784 Employees
Last Reported Date: 07/27/16

ck life sciences intl hldgs (775) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $3.8M
Chief Operating Officer, Vice President, Comp...
Total Annual Compensation: $10.2M
Chief Scientific Officer, Vice President and ...
Total Annual Compensation: $6.6M
Chief Investment Officer, Senior Vice Preside...
Total Annual Compensation: $2.0M
Compensation as of Fiscal Year 2015.
ck life sciences intl hldgs
CK Life Sciences Int'l., (Holdings) Inc. Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017

CK Life Sciences Int'l., (Holdings) Inc. Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017 . Venue: HILTON SAN FRANCISCO UNION SQUARE, 333 O'Farrell Street, San Francisco, CA 94102, United States.

CK Life Sciences Int'l., (Holdings) Inc. Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2016

CK Life Sciences Int'l., (Holdings) Inc. reported unaudited consolidated earnings results for the six months ended June 30, 2016. For the quarter, the company reported revenue of HKD 2,527,667,000 against HKD 2,449,263,000 a year ago. Profit before taxation was HKD 231,452,000 against HKD 206,169,000 a year ago. Profit for the period attributable to shareholders of the company was HKD 187,419,000 or 1.95 cents per basic and diluted share against HKD 178,666,000 or 1.86 cents per basic and diluted share a year ago. Net cash from operating activities was HKD 89,484,000 against HKD 79,061,000 a year ago. The Group has always been investing significantly in research and development activities. Such expenditure amounted to about HKD 82.9 million for the period ended 30 June 2016.

CK Life Sciences Int'l., (Holdings) Inc. to Report First Half, 2016 Results on Jul 27, 2016

CK Life Sciences Int'l., (Holdings) Inc. announced that they will report first half, 2016 results on Jul 27, 2016


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

775 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 775.
View Industry Companies

Industry Analysis


Industry Average

Valuation 775 Industry Range
Price/Earnings 21.9x
Price/Sales 1.3x
Price/Book 1.5x
Price/Cash Flow 18.8x
TEV/Sales 0.3x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CK LIFE SCIENCES INTL HLDGS, please visit www.ck-lifesciences.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.